A BILL 
To amend the Public Health Service Act to deem any insulin 
that is determined by the Secretary to be biosimilar 
to the reference product to be interchangeable with the 
reference product, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Biosimilar Insulin Ac-
4
cess Act of 2020’’. 
5
23:11 Sep 09, 2020
H8190
2 
•HR 8190 IH
SEC. 2. DEEMING BIOSIMILAR INSULIN TO BE INTER-
1
CHANGEABLE. 
2
(a) IN GENERAL.—Section 351(k)(3) of the Public 
3
Health Service Act (42 U.S.C. 262(k)(3)) is amended by 
4
adding at the end the following: 
5
‘‘(B) BIOSIMILAR INSULIN.— 
6
‘‘(i) DEEMED
INTERCHANGEABLE.— 
7
Notwithstanding paragraph (4), an insulin 
8
is deemed to be interchangeable with the 
9
reference product if the insulin is deter-
10
mined by the Secretary to be biosimilar to 
11
the reference product. 
12
‘‘(ii) SHORTENING EXCLUSIVITY FOR 
13
FIRST INTERCHANGEABLE PRODUCT.— 
14
‘‘(I) ACTION INSTITUTED.—If an 
15
action is instituted under subsection 
16
(l)(6) against the applicant that sub-
17
mitted the application for an insulin 
18
that is the first approved interchange-
19
able biosimilar biological product, 
20
paragraph (6) shall apply with respect 
21
to such insulin without regard to 
22
paragraph (6)(A). 
23
‘‘(II) 
ACTION
NOT
INSTI-
24
TUTED.—If such an action is not in-
25
stituted with respect to an insulin 
26
23:11 Sep 09, 2020
H8190
3 
•HR 8190 IH
that is approved as an interchangeable 
1
biosimilar biological product, the Sec-
2
retary shall make a determination on 
3
the interchangeability of any second 
4
or subsequent biological product with-
5
out regard to the delay otherwise re-
6
quired by paragraph (6). 
7
‘‘(iii) APPLICABILITY.—Clause (i) ap-
8
plies without regard to whether the insulin 
9
is determined to be biosimilar to the ref-
10
erence product, or deemed to be licensed 
11
pursuant to this section, before or after the 
12
date of enactment of the Biosimilar Insulin 
13
Access Act of 2020.’’. 
14
(b) CONFORMING CHANGES.—Section 351(k)(3) of 
15
the Public Health Service Act (42 U.S.C. 262(k)(3)) is 
16
amended— 
17
(1) by striking ‘‘Upon review’’ and inserting the 
18
following: 
19
‘‘(A) IN GENERAL.—Upon review’’; 
20
(2) by striking ‘‘(A) the Secretary’’ and insert-
21
ing the following: 
22
‘‘(i) the Secretary’’; 
23
(3) by striking ‘‘(i) is biosimilar’’ and inserting 
24
the following: 
25
23:11 Sep 09, 2020
H8190
4 
•HR 8190 IH
‘‘(I) is biosimilar’’; 
1
(4) by striking ‘‘(ii) can be’’ and inserting the 
2
following: 
3
‘‘(II) can be’’; and 
4
(5) by striking ‘‘(B) the applicant’’ and insert-
5
ing the following: 
6
‘‘(ii) the applicant’’. 
7
Æ 
23:11 Sep 09, 2020
H8190
